SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

Neptune tech and Bio-Resources (NEPT)

NEPT RSS Feed
Add NEPT Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board:
Last Post: 7/29/2016 10:14:48 AM - Followers: 21 - Board type: Free - Posts Today: 0
http://www.neptunebiotech.com/products 



I first heard about this stock when it was trading at the $2.32 mark a few weeks ago. Now we're hearing that more institutional buying and high profile firms are getting ready to take positions. That, in-turn, should lead to even more buying by retail investors. It's the stock snowball and visibility effect and this company deserves it 

About Neptune

Neptune Technologies & Bioressources Inc. researches, develops and commercializes proprietary bioactive ingredients and products with superior added-value and clinically proven health benefits. The Company extracts a range of bioactive ingredients such as novel proprietary omega-3 phospholipids from abundant yet underexploited marine biomass including Krill, a cold deep water zooplankton. Neptune's first commercially available product is Neptune Krill Oil (NKO®), which represents the only clinically proven and scientifically acknowledged marine omega-3 phospholipids with cardiovascular, cognitive and anti-inflammatory benefits for human applications and which exhibits unmet safety, purity and stability and consequently denoting a new level of excellence in omega-3 standards.

Neptune is pursuing market opportunities in the nutraceutical market including dietary supplements and functional foods. The Company is benefiting from opportunities in the pharmaceutical market through its pharmaceutical subsidiaries Acasti Pharma and NeuroBioPharm (including medical food, over-the-counter and prescription drug applications).

The Mission of Neptune is to:

  • Research, Develop and Commercialize Novel Marine Bioactive Ingredients
  • Pursue opportunities in the nutraceutical markets
    • Dietary Supplement
    • Functional Food
  • Exploit pharmaceutical applications
    • Subsidiary Acasti Pharma Inc: Cardiovascular diseases
    • Subsidiary NeuroBioPharm Inc.: Neurodegenerative diseases
  • Validate Superiority, Safety & Effectiveness
  • Protect Intellectual Property
  •   Enter Commercialization Alliances and Partnership Licenses

Promising results from A new cholesterol drug have helped call attention to Neptune, which is aiming for cholesterol/hyperlipidemia's ultimate prize, but unlike most companies dealing with clinical studies and regulatory approvals, Neptune is a revenue generating company whose products are already marketed and distributed in over 20 countries worldwide.

The Versant Partners' report, subtitled: "Krill oil franchise poised to outperform in multiple consumer and medical markets" features a few key points of note.

With NEPT's fiscal year end being February, Mr. Loe is calling for:

* F2012 revenues of $21.79 million and earnings $4.34 million ($0.09 EPS)
* F2013 revenues of $32.39 million and earnings of $8.81 million ($0.17 EPS)
* F2014 revenues of $45.37 million and earnings of $15.69 million ($0.30 EPS)
 
Loe cited management plans to meet forecasted demand by increasing current plant production from 130 thousand kilograms of krill oil per year to 430 thousand kilograms per year by 2015, a 300% production increase.
 
The report pinned its share price targets not only on the business Neptune has in hand, but also its future. By far, the biggest foundation Mr. Loe constructed on which to base his conclusions came from his meticulous research into the product itself - Neptune Krill Oil or NKO as it is branded on the market - and all its further refined products, such as Acasti's drug candidate called 'CaPre'.


Along the way, Loe also gives a significant nod to the functional food alliances Neptune developed with Yoplait - which is 50% owned by General Mills - and the food manufacturing behemoth, Nestle.

Mr. Loe wrote that both Yoplait and Nestle "should conclude development," of their research into Neptune Krill Oil by the end of the current year and that assuming all goes well, the sales of krill-oil infused food products by these giants would be a major revenue driver for Neptune in 2013/14  About Acasti

Acasti Pharma is developing safe and effective pharmaceutical and medical applications with an initial focus on cardiovascular disease by leveraging the intellectual property, clinical data and know how developed by Neptune Technologies. The Company is advancing a portfolio of bioactive ingredients of proprietary novel omega-3 phospholipids through the pharmaceutical development pathway which includes prescription medical foods (MF), over-the-counter products (OTC), and prescription drugs (Rx). Phospholipids are the major component of cell membranes and essential for all vital cell processes. They are one of the principle constituents of High Density Lipoprotein (good cholesterol) and play, as such, an important role in modulating cholesterol efflux.

Acasti Pharma's proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) stabilized by potent antioxidants. Evidence has demonstrated the anti-inflammatory properties of EPA and DHA regulating important biological functions including degenerative, arthritic, circulatory, digestive, and brain diseases. Delivering omega-3s functionalized on phospholipids helps optimize the omega-3 fatty acid therapeutic benefits. Potent antioxidants contribute to proper physiological regulation preventing free radical cellular damage, a common pathway for cardiovascular disease and inflammation as well as neurodegenerative disease 


 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
NEPT
Current Price
Volume:
Bid Ask Day's Range
SureTrader
NEPT News: Report of Foreign Issuer (6-k) 09/15/2016 04:51:39 PM
NEPT News: Report of Foreign Issuer (6-k) 08/05/2016 11:36:08 AM
NEPT News: Statement of Beneficial Ownership (sc 13d) 07/22/2016 04:10:32 PM
NEPT News: Report of Foreign Issuer (6-k) 07/15/2016 10:56:07 AM
NEPT News: Report of Foreign Issuer (6-k) 07/14/2016 05:11:06 PM
PostSubject
#202   Can anyone confirm these numbers? merushn 07/29/16 10:14:48 AM
#201   How long is this stock going to take losing money here 07/22/16 12:15:24 AM
#200   http://shortsqueeze.com/data.php?symbol=nept&submit=Short+Quote%99 total guchu 07/15/16 09:03:49 AM
#199   Conference call July 12, 2016 8 AM EST!! moneyjunkey 06/30/16 11:11:05 AM
#198   Great company, great product, great guidance!!! moneyjunkey 06/03/16 10:58:49 AM
#197   $NEPT Daily & Weekly Chart http://stock $Pistol Pete$ 05/30/16 04:40:26 PM
#196   NEPT PR this morning. Business better than expected Joe_NY 11/06/15 11:58:18 AM
#195   Wow, the earnings look good. Plus a lot Joe_NY 10/16/15 07:48:49 PM
#194   MAYBE N0 FAITH IN THE NEW CEO!!! Smitty99 12/04/14 03:48:11 PM
#193   $NEPT Neptune: Phase 2 Topline Win Welcomes Neptune maytepper 10/03/14 11:00:24 AM
#192   All out at 2.27. Looks like the conference rocketeer357 09/11/14 10:01:34 AM
#191   Back in here at 1.88 rocketeer357 09/04/14 06:51:25 AM
#190   Dumped approx 2.04 this morning at market open THREE-DAY-TRADER 08/07/14 12:48:46 PM
#189   riding this NEPT since 1.91 yesterday (Aug 5). THREE-DAY-TRADER 08/06/14 03:27:45 PM
#188   I'm a short term swing trader, so what THREE-DAY-TRADER 08/05/14 08:21:38 AM
#187   No idea. And no current position. I sold rocketeer357 08/05/14 08:02:56 AM
#186   You got a near term bottom in mind THREE-DAY-TRADER 08/04/14 11:48:46 AM
#185   Long NEPT rocketeer357 05/26/14 09:41:37 AM
#184   I am out (Thank God) But I think there RVL 05/25/14 05:16:20 PM
#183   This bad boy will be cash positive by Mack2387 03/28/14 02:27:40 PM
#182   Plant will be completed April 7, 2014 bucksynthesis 03/28/14 09:08:25 AM
#181   That is why I bought. :-) rayank 03/24/14 09:40:24 PM
#180   Double Bottom... Homelands 03/24/14 09:39:48 PM
#179   NEPT Bloomberg article "Foods Rich in Omega-3 May RVL 03/19/14 03:47:30 PM
#178   http://www.thelifesciencesreport.com/pub/na/15859 TLSR: Let's move on to a rado 02/28/14 02:43:16 AM
#177   I've seen some commercials for Schiff MegaRed krill rado 02/28/14 02:42:13 AM
#176   amatuer hour almost over gotinearly 01/24/14 09:59:19 AM
#175   Impressive strike $4 option volume expiring in Feb MrDanMan 01/23/14 03:54:03 PM
#174   Volume has picked up this week. Hope we MrDanMan 01/23/14 12:38:03 PM
#173   here we go baby!!! gotinearly 01/23/14 09:53:34 AM
#172   here we go baby!!! gotinearly 01/23/14 09:53:20 AM
#171   And another article. Good to see investing community MrDanMan 01/22/14 12:11:37 PM
#170   New Seeking Alpha article MrDanMan 01/21/14 01:02:51 PM
#169   Alex Russ on NEPT dr_airtime 12/22/13 05:47:11 PM
#168   Neptune and Aker BioMarine Reach Patent Infringement Settlement [SMART MONEY] 12/17/13 08:48:05 AM
#167   ~ $NEPT ~ Penny Roger$ 08/14/13 11:24:19 PM
#166   Net loss was ($3,379,000) for the current quarter, LGL8054 07/15/13 10:48:33 AM
#165   ~ $NEPT ~ Daily Par Sar Buy Signal Penny Roger$ 07/09/13 09:16:53 AM
#164   this thing is a bull-dozer... Andy68 01/15/13 01:08:12 PM
#163   this is looking good. i'm thinking about Andy68 01/13/13 04:29:43 PM
#162   Neptune Technologies's Acasti Pharma (ACST) subsidiary announced that mlkrborn 01/07/13 05:13:00 PM
#161   1.65 Wednesday, December 19 2012 7:13 AM, EST di4 12/19/12 08:14:00 AM
#160   Monday, 17 December, 2012 Sultan 12/19/12 02:11:23 AM
#159   NEPT - Neptune Technologies and Bioresources - $1.71 kookiekook 12/18/12 11:29:27 PM
#158   Neptune Technologies announces royalty prepayment agreement with Acasti mlkrborn 12/04/12 02:38:03 PM
#157   Nice little bounce today....hopefully will continue bcapps66 11/28/12 05:44:20 PM
#156   Yes, I always look forward to anything that GaryJPalys 11/17/12 04:00:58 AM
#155   Check this out.. Reassuring for NEPT as well Sultan 11/17/12 02:00:56 AM
#154   No problem.. APO.V, Acasti Pharma, 57% owned by Sultan 11/14/12 07:44:47 PM
#153   Thank you for keeping me informed Sultan :) GaryJPalys 11/13/12 04:14:42 AM
PostSubject